

## Ear Nose and Throat (ENT) Infections Antibiotic Guidelines

Salford Royal   
NHS Foundation Trust

University Teaching Trust

safe • clean • personal

**Classification:** Clinical Guideline  
**Lead Author:** Antibiotic Steering Committee  
**Additional author(s):** as above  
**Authors Division:** DCSS & Tertiary Medicine

**Unique ID:** 144TD(C)25(E3)  
**Issue number:** 4  
**Expiry Date:** January 2021

### Contents

|                  | Section  | Page |
|------------------|--|------|
| <i>Intro</i>     | <a href="#">Who should read this document</a>                        | 2    |
|                  | <a href="#">Key practice points</a>                                  | 2    |
|                  | <a href="#">Background/ Scope/ Definitions</a>                       | 2    |
|                  | <a href="#">What is new in this version</a>                          | 3    |
| <i>Guideline</i> | <a href="#">Guidelines for Ear Infections</a>                        | 3    |
|                  | <a href="#">Guidelines for Nasal and Para-nasal Infections</a>       | 5    |
|                  | <a href="#">Guidelines for Throat &amp; Neck Infections</a>          | 6    |
|                  | <a href="#">Roles and Responsibilities</a>                           | 8    |
|                  | <b>References</b>  |      |
|                  | <a href="#">Appendix</a>   | 8    |
|                  | <b>Document control information</b> (Published as separate document) | 9    |
|                  | Document Control   |      |
|                  | Policy Implementation Plan   |      |
|                  | Monitoring and Review  |      |
|                  | Endorsement  |      |
|                  | Equality analysis  |      |

## Who should read this document?

This policy applies to all clinical staff involved the prescribing of antimicrobials.

## Key Practice Points

This policy recommends empiric antimicrobial treatment options for adult patients with specified ear, nose and throat infections.

## Background

Antimicrobial agents are among the most commonly prescribed drugs and account for 20% of the hospital pharmacy budget. Unfortunately, the benefits of antibiotics to individual patients are compromised by the development of bacterial drug resistance. Resistance is a natural and inevitable result of exposing bacteria to antimicrobials.

Good antimicrobial prescribing will help to reduce the rate at which antibiotic resistance emerges and spreads. It will also minimise the many side effects associated with antibiotic prescribing, such as Clostridium difficile infection. It should be borne in mind that antibiotics are not needed for simple coughs and colds. In some clinical situations, where infection is one of several possibilities and the patient is not showing signs of systemic sepsis, a wait and see approach to antibiotic prescribing is often justified while relevant cultures are performed.

This document provides treatment guidelines for the most common situations in which antibiotic treatment is required. The products and regimens listed here have been selected by the Trust's Medicines Management Group on the basis of published evidence. Doses assume a weight of 60-80kg with normal renal and hepatic function. Adjustments may be needed for the treatment of some patients.

This document provides treatment guidelines for the appropriate use of antibiotics. The recommendations that follow are for empirical therapy and do not cover all clinical circumstances. Alternative antimicrobial therapy may be needed in up to 20% of cases. Alternative recommendations will be made by the microbiologist in consultation with the clinical team.

This document refers to the treatment of adult patients (unless otherwise stated).

Please refer to up to date BNF/SPC for a full list of cautions, contra-indications, interactions and adverse effects of individual drugs.

## What is new in this version?

- Centor criteria for assessing whether or not to prescribe antibiotics for a sore throat have been replaced with Fever Pain score in line with NICE.
- Addition of advice on treatment of Infected hearing implant (e.g.BAHA)

# Guideline

## Ear Infections

| Clinical diagnosis                                  | Antibiotic  | Duration    | Penicillin allergy  | Comments  |
|---|---|-------------|---|---|
| <b>Acute Localised Otitis Externa (furuncle)</b>    | Flucloxacillin oral 1g 6 hourly<br><br>Plus<br><br>Topical steroids   | 5 days      | Clarithromycin oral 500mg 12 hourly   | Prescribe IV initially in severe cases.   |
| <b>Acute Diffuse Otitis Externa (swimmer's ear)</b> | <b>Mild – moderate:</b><br><br>Topical Antimicrobial  | 7 days      |   |   |
|   | <b>Severe (e.g cellulitis or blocked ear canal):</b><br><br>Ciprofloxacin oral 500mg 12 hourly  | 7 days      |   | Topical drops to be prescribed at the discretion of the ENT consultant.   |
| <b>Perichondritis</b>                               | <b>1<sup>st</sup> line -</b><br>Ciprofloxacin oral 500mg – 750mg 12 hourly<br><br><b>2<sup>nd</sup> line –</b><br>Add clindamycin oral 450mg 6 hourly | 7 days      |   |   |
| <b>Malignant Otitis Externa</b>                     | Piperacillin / tazobactam IV 4.5g 8 hourly<br><br>Plus<br><br>Topical treatment<br><br>Oral Step down:<br><br>Ciprofloxacin                           | 4 – 6 weeks | Clindamycin IV 900mg 8 hourly <b>AND</b> Ciprofloxacin oral 500mg – 750mg 12 hourly | -Ensure swabs are taken prior to starting topical therapy<br>- Switch to orals based on clinical assessment and microbiological results<br>- Assess for any bone and intracranial extension |

|  |  |                       |  |   |
|--|--|-----------------------|--|---|
|  | oral 500mg – 750mg 12 hourly   |                       |  | - <b>All cases to be discussed with microbiology</b>  |
| <b>Acute Otitis Media</b>                                    | Antibiotics should <i>not</i> be routinely prescribed for uncomplicated AOM.<br><br>For severe disease or when risk of complications:<br><b>1<sup>st</sup> line</b> – Amoxicillin oral 500mg 8 hourly<br><br><b>2<sup>nd</sup> line</b> – Co-Amoxiclav oral 625mg 8 hourly | 5 days                | Antibiotics should <i>not</i> be routinely prescribed for uncomplicated AOM.<br><br>For severe disease or when risk of complications:<br><b>1<sup>st</sup> line</b> – clarithromycin oral 500mg 12 hourly<br><br><b>2<sup>nd</sup> line</b> – doxycycline oral 100mg 12 hourly<br><b>AND</b> metronidazole oral 400mg 8 hourly | - <b>Most cases are viral and self limiting.</b><br>- <b>Antibiotics should be delayed for 2-3 days and patient re-assessed.</b>                    |
| <b>Chronic Otitis Media</b>                                  | Topical treatment  | -                     | -  | Discuss with duty microbiologist if considering systemic antibiotics  |
| <b>Acute Mastoiditis</b>                                     | Co-Amoxiclav IV 1.2g 8 hourly<br><br>Oral Step down:<br>Co-amoxiclav 625mg 8 hourly  | 10 – 14 days          | Clindamycin IV 900mg 8 hourly <b>AND</b> Ciprofloxacin oral 500mg 12 hourly<br><br>Oral Step down:<br>Clindamycin oral 450mg QDS <b>AND</b> Ciprofloxacin oral 500mg 12 hourly   | IV to oral switch when clinically suitable (24 – 48hrs)<br>Review culture and sensitivity results<br>Assess for any bone and intracranial extension |
| <b>Infection of Bone Anchored Hearing Aid (BAHA) implant</b> | Co-amoxiclav 625mg 8 hourly  | 7-14 days then review | Clindamycin 450mg QDS  |   |

## Nasal and Para-nasal Sinus Infection

| Clinical diagnosis  | Antibiotic   | Duration | Penicillin allergy   | Comments  |
|---|--|----------|--|---|
| <b>Acute Rhinosinusitis</b>   | Antibiotics should ONLY be prescribed in SEVERE infection as this condition can have a viral cause.  |          |  |   |
| <b>Acute Bacterial Rhinosinusitis (severe or persistent symptoms)</b> | 1 <sup>st</sup> line –<br>Co-Amoxiclav oral 625mg 8 hourly<br><br>2 <sup>nd</sup> line –<br>Doxycycline oral 100mg 12 hourly   | 5 days   | 1 <sup>st</sup> line –<br>Clarithromycin oral 500mg 12 hourly<br><br>2 <sup>nd</sup> line –<br>Doxycycline oral 100mg 12 hourly  | -   |
| <b>Peri-orbital Cellulitis</b>  | Clindamycin IV 900mg 8 hourly <b>AND</b> Ciprofloxacin oral 500mg 12 hourly<br><br>Oral Step down:<br>Clindamycin oral 450mg QDS <b>AND</b> Ciprofloxacin oral 500mg 12 hourly | 2 weeks  | Clindamycin IV 900mg 8-hourly <b>AND</b> Ciprofloxacin oral 500mg 12 hourly<br><br>Oral Step down:<br>Clindamycin oral 450mg QDS <b>AND</b> Ciprofloxacin oral 500mg 12 hourly | - IV to oral switch when clinically suitable (24 – 48hrs) |

## Throat and Neck Infection

| Clinical diagnosis  | Antibiotic  | Duration | Penicillin allergy   | Comments   |
|---|---|----------|--|--|
| <b>Sore Throat</b>  | <p>Please note that sore throats can be viral in nature. These do NOT require antimicrobial therapy. Antibiotic treatment of adult pharyngitis benefits only those patients with GABHS infection. The Fever PAIN clinical score should be used to determine an appropriate prescribing strategy.</p> <p style="text-align: center;"><a href="#">FeverPAIN</a> clinical score</p> <p>Throat cultures are not recommended for the routine primary evaluation of adults with pharyngitis or for confirmation of negative results on rapid antigen tests.</p> |          |  |  |
| <p><b>Amoxicillin/Co-amoxiclav and glandular fever (Infectious mononucleosis):</b> A maculopapular rash often occurs following the administration of ampicillin or amoxicillin in patients with IM, and therefore these agents should not be used for empiric treatment of an acute sore throat. Development of a drug-related rash during IM does not appear to represent a true drug allergy, as patients subsequently tolerate ampicillin without an adverse reaction.</p> |   |          |  |  |
| <b>Pharyngitis / Tonsillitis</b>  | <p><b>Mild –</b><br/>Phenoxymethyl penicillin oral 500mg 6 hourly</p> <p><b>Mod-Severe –</b><br/>Benzylpenicillin IV 1.2g 6 hourly<br/>AND<br/>Metronidazole IV 500mg 8 hourly</p> <p>Oral Step down if no positive cultures:<br/>Penicillin V oral 500mg 6 hourly<br/>AND<br/>metronidazole oral 400mg 8hrly</p>   | 10 days  | <p><b>Mild –</b><br/>Clarithromycin oral 500mg 12 hourly</p> <p><b>Mod-Severe –</b><br/>Clindamycin IV 900mg 8 hourly</p> <p>Oral Step down if no positive cultures:<br/>Clindamycin oral 450mg 6 hourly</p> | <p>- IV to oral switch when clinically suitable (24 – 48hrs)</p> <p>Stop antibiotics if IM diagnosed and no positive culture</p> |
| <b>Quinsy (peritonsillar abscess)</b>   | <p>Benzylpenicillin IV 1.2g 6 hourly<br/>AND<br/>Metronidazole IV 500mg 8 hourly</p>  | 10 days  | <p>Clindamycin IV 900mg 8 hourly</p> <p>Oral Step down:<br/>Clindamycin oral 450mg 6 hourly</p>  |  |

|   |   |                 |  |   |
|---|---|-----------------|--|---|
|   | <p>Oral Step down:<br/>Penicillin V oral<br/>500mg 6 hourly<br/>AND<br/>metronidazole<br/>oral 400mg<br/>8hrly</p> <p>Above regimen<br/>may be<br/>insufficient for<br/>polymicrobial<br/>infection.<br/>If lack of clinical<br/>response and<br/>IM ruled out:</p> <p>Co-amoxiclav IV<br/>1.2g 8 hourly</p> <p>Oral Step down<br/>Co-amoxiclav<br/>oral 625mg 8<br/>hourly</p> |                 |  |   |
| <b>Epiglottitis</b>   | <p>Ceftriaxone IV<br/>2g OD</p> <p>Oral step down:<br/>Co-Amoxiclav<br/>625mg TDS</p>   | 7 – 10<br>days  | <p>Clindamycin IV<br/>900mg<br/>8 hourly <b>AND</b><br/>Ciprofloxacin oral<br/>500mg 12 hourly</p> <p>Oral Step down:<br/>Clindamycin oral<br/>450mg QDS <b>AND</b><br/>Ciprofloxacin oral<br/>500mg 12 hourly</p> | <p>- IV to oral switch<br/>when clinically<br/>suitable (24 –<br/>48hrs)</p> <p>- Review culture<br/>and sensitivity<br/>results</p>  |
| <b>Acute Laryngitis</b>   | Antibiotics are<br>NOT indicated  | -               | -  | -   |
| <b>Retropharyngeal<br/>Abscess /<br/>Lateral<br/>pharyngeal<br/>Abscess</b> | <p>Ceftriaxone IV<br/>2g OD <b>AND</b><br/>Metronidazole<br/>IV 500mg 8<br/>hourly</p> <p>Oral Step down:<br/>Co-Amoxiclav<br/>625mg TDS</p>  | 10 – 14<br>days | <p>IV Clindamycin<br/>900mg<br/>8 hourly <b>AND</b><br/>Ciprofloxacin oral<br/>500mg 12 hourly</p> <p>Oral Step down:<br/>Clindamycin oral<br/>450mg QDS <b>AND</b><br/>Ciprofloxacin oral<br/>500mg 12 hourly</p> | <p>-IV to oral switch<br/>when clinically<br/>suitable (24 –<br/>48hrs)</p> <p>- Review culture<br/>and sensitivity<br/>results</p> <p>- <b>All cases to be<br/>discussed with<br/>microbiology</b></p> |

|   |   |              |  |   |
|---|---|--------------|--|---|
|   |   |              |  |   |
| <b>Lemierre's Syndrome</b><br><br><b>(Suppurative Jugular Thrombophlebitis)</b> | Ceftriaxone IV 2g OD <b>AND</b> Metronidazole IV 500mg 8 hourly<br><br>Oral Step down: Co-amoxiclav 625mg TDS | 4-6 weeks    | Clindamycin IV 900mg 8 hourly<br><br>Oral Step down: Clindamycin oral 450mg 6 hourly | - IV to oral switch when clinically suitable (24 – 48hrs)<br>- Review culture and sensitivity results<br><b>- All cases to be discussed with microbiology</b> |
| <b>Suppurative Parotitis</b><br><br><b>(Salivary Gland Infection)</b>           | Co-Amoxiclav IV 1.2g 8-hourly<br><br>Oral Step down: Co-amoxiclav 625mg TDS                                   | 10 – 14 days | IV Clindamycin 900mg 8 hourly<br><br>Oral Step down: Clindamycin oral 450mg 6 hourly | - IV to oral switch when clinically suitable (24 – 48hrs)<br><br>- Review culture and sensitivity results   |

## Standards

- Document the Indication/rationale for antimicrobial therapy, including clinical criteria relevant to this.
- Review and document the patient's allergy status
- Ensure the choice of antibiotic complies with the antibiotic guidelines and you have documented any clinical criteria relevant to the choice of agent.
- Document a management plan including a stop or review date.
- Where relevant, consider drainage of pus or surgical debridement/removal of foreign material.

## Explanation of terms & Definitions

NA

## Roles and responsibilities

All clinical staff involved in the prescribing of antimicrobials to adhere to this policy including full documentation on EPMAR as detailed.

## Appendices

Not applicable



## References

- NICE<<https://cks.nice.org.uk/sore-throat-acute>
- PublicHealthEngland<[https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/664740/Managing\\_common\\_infections\\_guidance\\_for\\_consultation\\_and\\_adaptation.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/664740/Managing_common_infections_guidance_for_consultation_and_adaptation.pdf)>